Intensity Therapeutics (INTS) closed at $3.40 on October 30, 2026, up 1.8% from the previous close, on volume of 14,261 shares (30-day average 19,824).
Data as of October 30, 2026.
Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026
PRNewswire (Fri, 30-Oct 8:00 AM ET)
PRNewswire (Fri, 23-Oct 8:00 AM ET)
PRNewswire (Tue, 8-Sep 8:00 AM ET)
Globe Newswire (Tue, 11-Aug 11:00 AM ET)
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
PRNewswire (Tue, 11-Aug 7:31 AM ET)
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
PRNewswire (Tue, 4-Aug 8:00 AM ET)
Market Chameleon (Thu, 14-May 7:14 AM ET)
Market Chameleon (Thu, 12-Mar 4:14 AM ET)
Market Chameleon (Thu, 30-Oct 5:52 AM ET)
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Intensity Therapeutics trades on the NASDAQ stock market under the symbol INTS.
As of October 30, 2026, INTS stock price climbed to $3.40 with 14,261 million shares trading.
INTS has a beta of 2.79, meaning it tends to be more sensitive to market movements. INTS has a correlation of 0.06 to the broad based SPY ETF.
INTS has a market cap of $11.10 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, INTS traded as high as $286.00 and as low as $3.00.
The top ETF exchange traded funds that INTS belongs to (by Net Assets): VXF.
INTS has underperformed the market in the last year with a return of -49.0%, while the SPY ETF gained +11.0%. In the last 3 month period, INTS fell short of the market, returning -21.5%, while SPY returned +3.9%. However, in the most recent 2 weeks INTS has outperformed the stock market by returning +0.6%, while SPY returned -2.1%.
INTS support price is $3.11 and resistance is $3.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INTS shares will trade within this expected range on the day.
